In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections

被引：33

作者：

Amsler, Karen M. ^{[1
]}

Davies, Todd A. ^{[1
]}

Shang, Wenchi ^{[1
]}

Jacobs, Michael R. ^{[2
,3
]}

Bush, Karen ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA

[2] Case Western Reserve Univ, Cleveland, OH 44106 USA

[3] Univ Hosp Case Med Ctr, Cleveland, OH USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2008年 / 52卷 / 09期

关键词：

D O I：

10.1128/AAC.00336-08

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of <= 4 mu g/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.

引用

页码：3418 / 3423

页数：6

共 20 条

[1] Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin
Bogdanovich, T
Ednie, LM
Shapiro, S
Appelbaum, PC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) : 4210 - 4219
[2] In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections
Bradford, PA
Weaver-Sands, DT
Petersen, PJ
[J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 : S315 - S332
[3] Anti-MRSA β-lactams in development, with a focus on ceftobiprole:: the first anti-MRSA β-lactam to demonstrate clinical efficacy
Bush, Karen
Heep, Markus
Macielag, Mark J.
Noel, Gary J.
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (04) : 419 - 429
[4] Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents
Citron, Diane M.
Goldstein, Ellie J. C.
Merriam, C. Vreni
Lipsky, Benjamin A.
Abramson, Murray A.
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (09) : 2819 - 2828
[5] Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA
[6] Complicated infections of skin and skin structures: when the infection is more than skin deep
DiNubile, MJ
Lipsky, BA
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 : 37 - 50
[7] In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci
Hebeisen, P
Heinze-Krauss, I
Angehrn, P
Hohl, P
Page, MGP
Then, RL
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 825 - 836
[8] Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
Jauregui, LE
Babazadeh, S
Seltzer, E
Goldberg, L
Krievins, D
Frederick, M
Krause, D
Satilovs, I
Endzinas, Z
Breaux, J
O'Riordan, W
[J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) : 1407 - 1415
[9] In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci
Jones, RN
Deshpande, LM
Mutnick, AH
Biedenbach, DJ
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) : 915 - 932
[10] Lee Su Young, 2005, Surg Infect (Larchmt), V6, P283, DOI 10.1089/sur.2005.6.283

← 1 2 →